Answers go deeper than the script: questioning keeps surfacing new concrete detail behind a positive development · compa
The model's full reasoning — Q1 2022 call → NOWe need to evaluate both gates based on the transcript. Gate 1: Is there a positive current development that management presents as going well, and does the Q&A produce more concrete operating detail than the prepared remarks? The call discusses EscharEx Phase 2 results, NexoBrid BLA progress, etc. The main positive current development is the EscharEx Phase 2 data, which is presented as positive. In the Q&A, analysts ask about the use of nonsurgical debridement, the potential for EscharEx to replace sharp debridement, and the pivotal study design. Management and Dr. Dove provide additional details about how EscharEx works in practice, its precision, and its potential as first-line therapy. However, does the Q&A produce more concrete operating detail than the prepared remarks? The prepared remarks already detailed the Phase 2 results, endpoints, and comparisons. The Q&A adds some clinical perspective from Dr. Dove about her experience, but it's largely qualitative. The questions about pivotal study design are answered with "premature" and no specifics. The Q&A does not seem to add substantial new operational specifics about the development itself—like volumes, customers, timing, etc. The development is the clinical trial results, which are already presented. The Q&A mostly repeats or elaborates on the same points. There is no new concrete detail about actual business activity, like partnerships, sales, or execution. The NexoBrid BLA is also mentioned, but the Q&A doesn't probe that much. The Q&A about EscharEx is more about clinical practice and potential, not about concrete operational progress. So Gate 1 might be NO because the Q&A doesn't add substantially new concrete specifics beyond the prepared remarks. The prepared remarks already gave the data. The Q&A adds some anecdotal experience but not new operational facts. Also, the development is a clinical trial result, which is a current positive development, but the Q&A doesn't produce more concrete operating detail—it's more of the same. So Gate 1 likely NO. Gate 2: Is the development chiefly something the company itself created and controls? The EscharEx product is the company's own product, so the development is its own. But the momentum is based on clinical trial results, which are internal. However, the question is about the main positive development that management highlights and analysts probe.
The model's full reasoning — Q2 2018 call → NOWe need to evaluate two gates based only on the transcript. Gate 1: Is there a positive, current development in the company's business that management presents as genuinely going well or stepping up right now, and in the Q&A, the discussion produces more concrete operating detail than the prepared remarks contained? That is, as analysts ask about that development, do management's answers keep adding new, specific, present-tense substance about it? We need to identify a positive current development. The prepared remarks mention several things: completion of enrollment in U.S. Phase 3 clinical trial of NexoBrid (DETECT study), expected top-line data around end of year. Also expansion of Phase 3 CIDS study to U.S., marketing authorization in South Korea, humanitarian aid in Guatemala, FDA agreement on development pathway for mass injuries, EscharEx protocol submission planned. Also strategic discussions with multiple parties. In the Q&A, analysts ask about EscharEx market and reimbursement, and about NexoBrid study details (average body surface area), and about strategic transaction. Also about NOLs. Let's see if any positive development is probed with additive detail. First question from Bruce Nudell about chronic wound treatment and EscharEx. He asks about expectations for EscharEx given pivotal trials focus on DFUs and VLUs. Gal Cohen responds with market analysis details: 8.7 million Americans with chronic wounds, 5 million with VLUs and DFUs, 1.3 million debridement procedures, cost $1,000-$2,000, $2 billion market. He also says physicians would think it relevant for other indications. This is more detail about market opportunity, but is it about a current development? EscharEx is not yet approved; it's a plan. The prepared remarks said "we are on track to submit a protocol to the FDA in the second part of this year for the EscharEx clinical development program." So EscharEx is not a current positive development with actual activity; it's a future plan. The Q&A about EscharEx is about market opportunity and reimbursement, not about current execution. So that doesn't qualify. Second question from Bruce Nudell about reimbursement for EscharEx. Gal Cohen explains commercial strategy, relying on existing reimbursement code, etc. Again, this is about future plans, not current development.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MNDY | monday.com Ltd. | Q4 2024 | 2024-05-15 | A |
| ZLAB | Zai Lab Limited | Q1 2024 | 2024-05-09 | B |
| YOU | Clear Secure, Inc. | Q1 2024 | 2024-05-08 | C+ |
| STIM | Neuronetics, Inc. | Q1 2024 | 2024-05-07 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q1 2024 | 2024-04-24 | A |
| CSGP | CoStar Group, Inc. | Q1 2024 | 2024-04-23 | B+ |
| SAP | SAP SE | Q1 2024 | 2024-04-22 | B |
| AREC | American Resources Corporation | Q4 2023 | 2024-03-28 | F |
| QRHC | Quest Resource Holding Corporation | Q4 2023 | 2024-03-12 | C+ |
| ALKT | Alkami Technology, Inc. | Q4 2023 | 2024-03-02 | A |
| MCW | Mister Car Wash, Inc. | Q4 2023 | 2024-02-21 | D |
| TYL | Tyler Technologies, Inc. | Q4 2023 | 2024-02-15 | C+ |
| GDDY | GoDaddy Inc. | Q4 2023 | 2024-02-13 | B+ |
| SYY | Sysco Corporation | Q2 2024 | 2024-01-30 | B+ |
| STLD | Steel Dynamics, Inc. | Q4 2023 | 2024-01-24 | C+ |
| CSPI | CSP Inc. | Q4 2023 | 2023-12-12 | D |
| ATXS | Astria Therapeutics, Inc. | Q3 2023 | 2023-11-13 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| VCEL | Vericel Corporation | Q3 2023 | 2023-11-08 | A |
| SG | Sweetgreen, Inc. | Q3 2023 | 2023-11-04 | D |
| CHRD | Chord Energy Corporation | Q3 2023 | 2023-11-02 | A |
| PLTR | Palantir Technologies Inc. | Q3 2023 | 2023-11-02 | B |
| REGN | Regeneron Pharmaceuticals, Inc. | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| GSK | GSK plc | Q3 2023 | 2023-11-01 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| MNSO | MINISO Group Holding Limited | Q4 2023 | 2023-08-22 | A |
| PFGC | Performance Food Group Company | Q4 2023 | 2023-08-16 | B+ |
| DNUT | Krispy Kreme, Inc. | Q2 2023 | 2023-08-10 | C |
| RBLX | Roblox Corporation | Q2 2023 | 2023-08-09 | C+ |
| PODD | Insulet Corporation | Q2 2023 | 2023-08-08 | B+ |
| MVST | Microvast Holdings, Inc. | Q2 2023 | 2023-08-07 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| CIVI | Civitas Resources, Inc. | Q2 2023 | 2023-08-03 | B |
| IDT | IDT Corporation | Q3 2023 | 2023-06-05 | C |
| STIM | Neuronetics, Inc. | Q1 2023 | 2023-05-13 | B |
| VECO | Veeco Instruments Inc. | Q1 2023 | 2023-05-08 | B |
| LTH | Life Time Group Holdings, Inc. | Q1 2023 | 2023-04-25 | A |
| SCPH | scPharmaceuticals Inc. | Q4 2022 | 2023-03-22 | C+ |
| COCO | The Vita Coco Company, Inc. | Q4 2022 | 2023-03-08 | B |
| PBPB | Potbelly Corporation | Q4 2022 | 2023-03-02 | A |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| LANC | Lancaster Colony Corporation | Q2 2023 | 2023-02-02 | B+ |
| NVS | Novartis AG | Q4 2022 | 2023-02-01 | B |
| RELL | Richardson Electronics, Ltd. | Q2 2023 | 2023-01-05 | B+ |
| CUTR | Cutera, Inc. | Q3 2022 | 2022-11-05 | C |
| MUR | Murphy Oil Corporation | Q3 2022 | 2022-11-03 | B+ |
| LPX | Louisiana-Pacific Corporation | Q3 2022 | 2022-11-01 | B+ |
| INMD | InMode Ltd. | Q3 2022 | 2022-10-27 | B+ |
| INVZ | Innoviz Technologies Ltd | Q2 2022 | 2022-08-10 | D |
| FLGT | Fulgent Genetics, Inc. | Q2 2022 | 2022-08-04 | C+ |
| GTHX | G1 Therapeutics, Inc. | Q1 2022 | 2022-08-03 | D |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| TMUS | T-Mobile US, Inc. | Q2 2022 | 2022-07-27 | B+ |
| AZO | AutoZone, Inc. | Q3 2022 | 2022-05-24 | B+ |
| AXON | Axon Enterprise, Inc. | Q1 2022 | 2022-05-10 | B+ |
| VEV | Vicinity Motor Corp. | Q4 2021 | 2022-03-30 | D |
| HRTX | Heron Therapeutics, Inc. | Q4 2021 | 2022-02-28 | D |
| INCY | Incyte Corporation | Q4 2021 | 2022-02-08 | C+ |
| TMDX | TransMedics Group, Inc. | Q3 2021 | 2021-11-09 | C+ |
| ATRC | AtriCure, Inc. | Q3 2021 | 2021-11-03 | C |
| SUPN | Supernus Pharmaceuticals, Inc. | Q3 2021 | 2021-11-03 | C+ |
| ZI | ZoomInfo Technologies Inc. | Q3 2021 | 2021-11-01 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CHWY | Chewy, Inc. | Q2 2021 | 2021-09-01 | B |
| VVV | Valvoline Inc. | Q3 2021 | 2021-08-06 | B+ |
| TIGO | Millicom International Cellular S.A. | Q2 2021 | 2021-07-31 | B+ |
| SAP | SAP SE | Q2 2021 | 2021-07-21 | B+ |
| UPWK | Upwork Inc. | Q3 2018 | 2018-11-11 | B+ |
| MYO | Myomo, Inc. | Q3 2018 | 2018-11-05 | C |
| CFG | Citizens Financial Group, Inc. | Q3 2018 | 2018-10-19 | A |
| UAL | United Airlines Holdings, Inc. | Q3 2018 | 2018-10-17 | B+ |
| INSP | Inspire Medical Systems, Inc. | Q2 2018 | 2018-08-12 | A |
| REI | Ring Energy, Inc. | Q2 2018 | 2018-08-09 | B |
| GAIA | Gaia, Inc. | Q2 2018 | 2018-08-06 | B+ |
| RNG | RingCentral, Inc. | Q2 2018 | 2018-08-06 | A |
| FRPT | Freshpet, Inc. | Q2 2018 | 2018-08-06 | B+ |
| TSLA | Tesla, Inc. | Q2 2018 | 2018-08-02 | B |
| OOMA | Ooma, Inc. | Q1 2019 | 2018-05-22 | A |
| ZG | Zillow Group's | Q1 2018 | 2018-05-08 | C+ |
| QLYS | Qualys, Inc. | Q1 2018 | 2018-05-02 | B+ |
| CPS | Cooper-Standard Holdings Inc. | Q1 2018 | 2018-05-02 | B |
| VRTX | Vertex Pharmaceuticals Incorporated | Q1 2018 | 2018-04-26 | C+ |
| SYK | Stryker Corporation | Q1 2018 | 2018-04-26 | B+ |
| TNC | Tennant Company | Q4 2017 | 2018-02-22 | B |
| TMUS | T-Mobile US, Inc. | Q4 2017 | 2018-02-09 | B+ |
| NICE | NICE Ltd. | Q3 2017 | 2017-11-04 | A |
| SAMG | Silvercrest Asset Management Group Inc. | Q3 2017 | 2017-11-03 | A |
| VC | Visteon Corporation | Q3 2017 | 2017-10-28 | B+ |
| PRO | PROS Holdings, Inc. | Q3 2017 | 2017-10-26 | B+ |
| SRPT | Sarepta Therapeutics, Inc. | Q3 2017 | 2017-10-26 | C+ |
| CAL | Caleres, Inc. | Q2 2017 | 2017-08-29 | B+ |
| LITE | Lumentum Holdings Inc. | Q4 2017 | 2017-08-09 | B+ |
| FRPT | Freshpet, Inc. | Q2 2017 | 2017-08-07 | B+ |
| INTU | Intuit Inc. | Q3 2017 | 2017-05-23 | B+ |
| ADAP | Adaptimmune Therapeutics plc | Q1 2017 | 2017-05-10 | D |
| ISDR | Issuer Direct Corporation | Q1 2017 | 2017-05-06 | C |
| XPO | XPO Logistics, Inc. | Q1 2017 | 2017-05-04 | B |
| SRPT | Sarepta Therapeutics, Inc. | Q1 2017 | 2017-04-28 | D |
| SAH | Sonic Automotive, Inc. | Q1 2017 | 2017-04-26 | C |
| SYK | Stryker Corporation | Q4 2016 | 2017-01-24 | C+ |
| MCS | The Marcus Corporation | Q3 2016 | 2016-10-27 | C+ |
| GSK | GSK plc | Q3 2016 | 2016-10-26 | B |
| VYGR | Voyager Therapeutics, Inc. | Q2 2016 | 2016-08-11 | A |
| SQ | Square's | Q2 2016 | 2016-08-04 | A |
| DGII | Digi International Inc. | Q3 2016 | 2016-07-28 | B |
| PAR | PAR Technology Corporation | Q1 2016 | 2016-05-04 | D |
| PM | Philip Morris International Inc. | Q1 2016 | 2016-04-19 | B+ |
RBLX · Q2 2023 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES The transcript shows a clear positive current development in advertising, where management's prepared remarks mention live ads, 200 activations, 19% of top 100 with ad units, and some demand exceeding supply. In the Q&A, they add fresh specifics like pricing strategy (gentle now, floating later), new ad unit types, 12% of top 100 using portals, demand in 17-24 female cohort, self-serve options, and brand volume challenges. These details are operational and additive across multiple exchanges, meeting GATE 1 criteria. For GATE 2, advertising is driven by Roblox's own creation and control: 200 activations, portal ad units, self-serve platform, and rollout execution. It's not reliant on external industry tailwinds but on their platform improvements and brand engagement. This satisfies the primary engine condition.
SG · Q3 2023 → YESThe task is to evaluate two gates based on the Sweetgreen earnings call transcript and return YES only if both gates are YES, otherwise NO. YES The transcript shows a clear positive current development in Infinite Kitchen, with management's Q&A responses adding substantial new operational details—such as first-unit performance, customer experience improvements, margin leverage, AUV targeting, retrofit opportunities, and throughput optimizations—that go beyond the prepared remarks' high-level plans. This satisfies Gate 1 criteria for additive, substantive detail across multiple exchanges. For Gate 2, Infinite Kitchen is a proprietary technology the company developed and controls, with momentum driven by its own execution, customer adoption, and operational refinements rather than external tailwinds, making it the primary engine.
ALKT · Q4 2023 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES The transcript shows a clear positive current development in the bank's market progress and add-on sales momentum, with Q&A providing substantial new operational details like specific backlog numbers, implementation timelines, product adoption rates, and customer-specific challenges that go beyond the prepared remarks. For GATE 2, the primary engine is Alkami's own platform, cloud-native architecture, and execution on replacements of legacy systems, which would largely continue even if external conditions shifted, as the company is actively winning share through its controlled rollout and product improvements.